Privately held biotech PhenoMatriX Inc. (PMX) isn't yet ready for prime time, and company president and CEO Kosta Steliou is loath to suggest a commercialization timetable.
Switzerland's Cytos Biotechnology Ltd. stepped away from the ledge of a financial precipice and rescued its lead immunodrug candidate CYT003-QbG10 by forging agreements with a syndicate of international investors to raise up to CHF37 million (US$40.6 million) in equity and debt.
Cardium Therapeutics Inc. initiated a Phase III registration study of lead product candidate Generx (alferminogene tadenovec, Ad5FGF-4) in myocardial ischemia.
Shares of Ampio Pharmaceuticals Inc. soared Monday after the biopharmaceutical company reported positive data from its interim review of the first 50 percent of patients enrolled in a Phase II study of Optina in diabetic macular edema (DME).
Ireland's Shire plc bulked up its hematology business by scooping up small biotech FerroKin BioSciences Inc. for $100 million in up-front cash, plus potential milestone payments of up to $225 million based on achieving clinical development, regulatory and net sales targets.
ProNAi Therapeutics Inc. became the second biotech to validate a savvy technology purchase by Marina Biotech Inc., extending its license for Marina's "Smarticles" liposomal delivery technology – used in its nucleic acid-based DNA interference (DNAi) therapies – from the clinic to potential commercialization.
San Diego biotech HemaQuest Pharmaceuticals Inc. closed a $13 million extension of its Series B financing to fund a Phase IIb study of its lead candidate HQK-1001 in sickle cell disease.
Shares of Medivation Inc. and Dendreon Corp. took opposite trajectories Thursday after Janssen Research & Development LLC unblinded its Phase III study of Zytiga (abiraterone acetate) plus prednisone in asymptomatic or mildly symptomatic patients with metastatic castration-resistant prostate cancer (CRPC) who had not received chemotherapy.
Persistence paid off for Discovery Laboratories Inc., whose synthetic, peptide-containing surfactant Surfaxin (lucinactant intratracheal suspension) received FDA approval late Tuesday for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for the condition.
Canadian biopharma Medicago Inc. clinched a strategic alliance with Japan's Mitsubishi Tanabe Pharma Corp. (MTPC) by executing a master research collaboration agreement to develop and commercialize at least three vaccines using its virus-like particle (VLP) technology.
